Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Renal Cell Carcinoma (aRCC)”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Not applicableStudy completedNCT04957160
What this trial is testing

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)
Ipsen 281
Not applicableStudy completedNCT05394493
What this trial is testing

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Who this might be right for
Advanced Renal Cell Carcinoma
Pfizer 130
Not applicableStudy completedNCT05444933
What this trial is testing

Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.

Who this might be right for
Advanced Renal Cell Carcinoma
Ipsen 252
Testing effectiveness (Phase 2)Looking for participantsNCT07188896
What this trial is testing

Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)Metastatic Renal Cell Carcinoma ( mRCC)Clear Cell Renal Cell Carcinoma (ccRCC)
Brian Rini 120
Not applicableStudy completedNCT04682587
What this trial is testing

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Pfizer 481
Not applicableStudy completedNCT05361434
What this trial is testing

The Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Who this might be right for
Advanced Renal Cell Carcinoma
Ipsen 311
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07159191
What this trial is testing

Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)
Peking Union Medical College Hospital 30
Not applicableStudy completedNCT04637204
What this trial is testing

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Who this might be right for
Renal Cell Carcinoma
Ipsen 1,540
Not applicableStudy completedNCT04043975
What this trial is testing

Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Who this might be right for
Advanced or Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb 286
Not applicableEnded earlyNCT05534789
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Who this might be right for
Carcinoma, Renal Cell
Pfizer 106
Not applicableStudy completedNCT06345183
What this trial is testing

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Who this might be right for
Advanced Renal Cell Carcinoma (aRCC)
Bristol-Myers Squibb 327
Not applicableStudy completedNCT00610012
What this trial is testing

Tumor Registry of Advanced Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
iOMEDICO AG 1,500